Skip to content

Trial Summary

A Phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-l1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable Triple-Negative Breast Cancer

Acronym:

ALEXANDRA_I Mpassion030

ACTRN/NCT /ethics:

NCT03498716

Scientific title:

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Sponsor / Cooperative group:

Hoffmann-La Roche

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2018-08-02
Anticipated End Date2025-08-31

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Emailsue.yeend@icon.team
Phone08 8292 2204
Principal InvestigatorDr Kerry Cheong
Recruitment StatusRecruiting